Proud to see our Íñigo González Larreategui presenting a flash talk and poster at #aseicacongress in Bilbao on the therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes. 👏 @aseica.bsky.social

10.10.2025 08:03 — 👍 1    🔁 1    💬 0    📌 0

Intense week for @LSoucekLab! We are happy to see our @dcapi14 presenting a poster on Targeting oncogene cooperation: MYC inhibition enhances response and overcomes resistance to KRAS inhibitors. #TargetingRAS2025 @TargetingRAS Targeting RAS symposium, Salamanca, 2025 👏💪

10.10.2025 07:58 — 👍 0    🔁 0    💬 0    📌 0

MYC in cancer: from undruggable target to clinical trials Nature Reviews Drug Discovery - Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on...

We are delighted to share that the review “MYC in cancer: from undruggable target to clinical trials” by Jonathan Whitfield and @lsoucek.bsky.social is finally out in Nature Review Drug Discovery. What an amazing journey this has been and still promises to be!
rdcu.be/eawOK

19.02.2025 20:27 — 👍 2    🔁 0    💬 0    📌 0

@lsoucek.bsky.social is presenting today a seminar at UB regarding the challenge associated to the development of a MYC inhibitor. Info below.

06.02.2025 10:34 — 👍 3    🔁 0    💬 0    📌 0